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ABSTRACT
Introduction: Updated guidelines from the WHO
recommend antiretroviral treatment for adults with HIV
at any CD4 count and daily oral pre-exposure
prophylaxis (PrEP) for people at substantial risk of HIV
infection. However, implementation challenges may
hinder the ability of programmes to translate these
recommendations into successful practice. This
demonstration project is the first to integrate PrEP and
immediate treatment (ITx) for female sex workers
(FSWs) in South Africa to answer operational research
questions.
Methods and analysis: This is a prospective cohort
study where the main outcome is retention at
12 months. The study population is recruited into two
arms across two urban sites: (1) PrEP for HIV-negative
FSWs (n=400) and (2) ITx for HIV-positive FSWs with
CD4 greater than national guidelines (n=300). We
investigate process and other health indicators, uptake
and use of PrEP and ITx through qualitative research,
and evaluate cost-effectiveness analysis combined with
estimates of impact through epidemiological modelling.
Ethics and dissemination: The Treatment And
Prevention for female Sex workers in South Africa
(TAPS) Project was designed as an implementation
study before emtricitabine/tenofovir disoproxil fumarate
was licenced as an indication for PrEP in South Africa.
Therefore, clinical trial requirements for ethical and
South African Medicines Control Council approvals
were followed. Results will be disseminated to
participants, local health officials and other
stakeholders, as well as in peer-reviewed journals and
at conferences.
INTRODUCTION
Globally, UNAIDS data have shown a signiﬁ-
cant and continuous decline (35%) in the
number of new HIV infections since 2000.1
In sub-Saharan Africa, this trend is even
more pronounced with a 41% decline.
However, in this region of the world, where
women make up for more than half of all
people living with HIV, incidence rates
remain high.1 In particular, the HIV epi-
demic in South Africa continues to be the
highest in the world, based on both HIV inci-
dence (with a currently estimated rate of up
to 4 per 100 women-years2 3) and total
number of people living with HIV (6.8
million estimated in 2014.4 5
The South African National Strategic Plan
on HIV, sexually transmitted infections (STIs)
and tuberculosis for 2012–20166 prioritises
interventions with the aim to reduce new
infections on a national level by 50% using
combination prevention while scaling up
treatment to cover at least 80% of the popula-
tion. It also identiﬁes key populations as a
major focus of the strategy, which calls for a
multifaceted approach to ending the epi-
demic. Sex workers are among the key popu-
lations identiﬁed in the past and current
National Strategic Plans. Globally, female sex
workers (FSWs) are 13.5 times more likely to
be living with HIV than women in the general
population.7 The 2013 South African Key
Populations Report estimates that HIV pre-
valence among FSWs is between 44 and
69%,8–11 with 19.8% of all new infections
being attributed to sex work, including infec-
tions among clients and partners of clients.12
Strengths and limitations of this study
▪ The Treatment And Prevention for female Sex
workers in South Africa study incorporates a
multidisciplinary service delivery evaluation
within an implementation science paradigm.
▪ Success will be measured using several out-
comes enabling triangulation of data.
▪ The study was designed to adapt to shifts in
South African antiretroviral therapy guidelines
and clinical standards.
▪ The study will not measure the effectiveness of
any service delivery model as there is no com-
parison arm.
▪ Our sample size is relatively small and might not
be representative of the national population of
female sex workers.
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A study conducted in 2008 in a cohort of high-risk
women in KwaZulu-Natal Province, estimated incidence
to be as high as 7.2/100 person-years.11 More recently, a
prevalence study conducted among populations of sex
workers found a 72% HIV prevalence with low treatment
uptake in Gauteng Province.13 This high vulnerability is
rooted in the many structural drivers of HIV risk affecting
this population including: restricted access to healthcare,
criminalisation and lack of legal protection, unsafe
working conditions, stigma, and economic hardship.12 As
a marginalised population who are stigmatised and crimi-
nalised, sex workers require specialised programmes sen-
sitive to their needs for interventions in HIV prevention,
care and treatment as well as support to access other
health and legal services.
Following the positive results of antiretroviral
(ARV)-based prevention studies in reducing both HIV
transmission (through ITx) and acquisition (through
PrEP),14–20 global and national authorities updated HIV
guidelines to recommend antiretroviral therapy (ART) be
initiated at any CD4 count in adults and daily oral PrEP as
an additional prevention strategy for people at substantial
risk of HIV infection.21–23 While modelling studies have
shown that the scaling up of new prevention and treat-
ment tools across the HIV continuum of care could have
a signiﬁcant impact on the epidemic,24–26 implementa-
tion challenges relating to health service capacity, accept-
ability and ﬁnancing and resource allocation may hinder
the ability of the programmes from making a signiﬁcant
difference to the HIV epidemic.27 28
The evaluation of existing and innovative models of care
to implement new technologies for prevention and treat-
ment through demonstration projects is being conducted
around the world.29 These projects represent a spectrum of
designs from clinical trial-like protocols to ‘real-world’
implementation science studies, yet all have similar goals: to
test delivery models of new technologies and interventions
to inform policy and programming. In particular, projects
tend to cater to key populations where acceptability and
uptake of technologies such as oral PrEP may be higher and
intersect with those populations who might beneﬁt the
most initially, such as men who have sex with men, sex
workers, serodiscordant couples and young women. These
prevention-focused projects are situated within a landscape
of evolving HIV treatment guidelines, as treatment is now
recognised as the major contributor to prevention and thus
many include treatment components.21 30
The demonstration project described here is the ﬁrst
to integrate a combination prevention intervention
including oral PrEP and ITx (for those with CD4 counts
higher than current national guidelines) for FSWs in
South Africa.i The interventions are being delivered at
two clinic-based sites for FSWs in Gauteng Province.
Gauteng is the most densely populated province of
South Africa, also home to both the economic and polit-
ical capitals of the country.31 This implementation study
seeks to understand the ‘real-world’ implications of
introducing PrEP and ITx into an existing service deliv-
ery structure. By combining PrEP and ITx, we aim to
leverage, in a novel way, the service delivery areas
needed to support these programmes which primarily
include outreach for testing and counselling and clinic
services. The overall aim will be to answer operational
questions: whether FSWs will accept ITx or combination
prevention including PrEP, whether the service delivery
mechanism is capable of handling the increase in
resource needs these interventions might lead to, and
what kind of implications this strategy would have on
overall costs, should they be considered for scale up.
METHODS AND ANALYSIS
Population and setting
FSWs are the study population deﬁned as women self-
identifying as sex workers, and who have received goods
or money in exchange for sex in the past 3 months, age
18 or above, operating in the areas surrounding two
existing clinics providing services for sex workers in
Hillbrow, Johannesburg and the central business district
in Pretoria. These clinics are run by Wits Reproductive
Health and HIV Institute (RHI), one of the largest
research Institutes of the University of Witswatersrand;
since 1994, Wits RHI has pioneered health programmes
with a strong community focus. The Hillbrow site is con-
nected to the Esselen Clinic which is home to the well-
established Wits RHI Sex Worker Project.32 The Sex
Worker Project is a comprehensive reproductive health,
HIV and STI prevention and treatment service pro-
gramme partnered with City of Johannesburg and the
South African Department of Health (DoH). It provides
services such as: HIV counselling and testing and
condom distribution, nurse-initiated and managed ART
(NIMART), tuberculosis screening, human papilloma-
virus screening, clinical services for minor ailments, psy-
chosocial support and referrals to both clinical and legal
services. The programme accesses several brothels, with
mobile units to serve street-based sex workers and a sta-
tionary clinic space. The actual clinic space for the
Treatment And Prevention for female Sex workers in
South Africa (TAPS) Demonstration Project is located in
the Wits RHI Research and Training Centre, which is
adjacent to the Esselen Clinic. At the time we initiated
the study, renovations at the Esselen Clinic had begun
and the building was closed which is the reason for
housing the TAPS Project in the Research Centre.
The Pretoria site is located in Sediba Hope Medical
Centre, a private non-proﬁt clinic afﬁliated with the
Department of Health, which has been serving the local
community in the heart of the inner city of Pretoria.
Wits RHI’s Sex Worker Project has now opened a sex
iRecently ( June 2016), the NDoH started the piloting at 10 sites of new
National guidelines for treatment, where all people infected with HIV
independent of their CD4 count are eligible and pre-exposure
prophylaxis is available for female sex workers. This demonstration
project is informing the roll out pilot directly.
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worker clinic at Sediba Hope which is also linked to the
Community Health Clinic in the same building.
Design
The study design is a prospective, observational cohort
study, with two study arms:
1. PrEP intervention as part of a combined prevention
approach for recently documented HIV-negative FSWs;
2. ITx intervention for HIV-positive ART-naïve FSWs
not eligible for ART at the currently implemented
CD4-deﬁned standard of care.
The PrEP intervention arm will seek to protect
HIV-negative FSWs from acquiring HIV through the use
of PrEP and other available prevention options (such as
condoms). The ITx intervention arm will seek to link
FSWs directly to care to reduce and avoid loss to
follow-up within the treatment cascade. Indirectly, it will
seek to prevent HIV-positive FSWs from transmitting the
virus to clients and other sex partners through the use
of ARVs.
Sample size and eligibility criteria
Table 1 shows the sample size considerations for both
study arms. We aim to enrol 400 FSWs in the PrEP arm
of the study. With an expected retention rate of 65%
(precision of ±5%) at 12 months, we need 350 partici-
pants, which we have increased to 400 to account for
variability across the two sites. To achieve this sample
size, we should aim to screen 1600 FSWs, of which 800
are expected to be HIV-negative (assuming an HIV
prevalence of 50%) and we estimate conservatively that
50% accept to participate. For the ITx arm, we aim to
enrol 300 FSWs with an expected retention rate of 75%
(precision of ±5%) at 12 months, assuming a 25%
default rate which reﬂects recent research on the treat-
ment cascade.33 To achieve this sample size, we should
aim to screen 3600 FSWs, of which 1800 are expected to
be HIV-positive (assuming an HIV prevalence of 50%),
one-third with CD4 counts over 350 (n=600) and 50%
accept to participate. In practice, the screening process
is a joint step in the recruitment of both the PrEP and
the ITx arms. As such, we will aim to screen 3600 FSWs
to be able to achieve the required sample sizes. PrEP
enrolment will stop as soon as the required sample size
is achieved. Note that the original calculations for this
study were performed assuming a national CD4 count
initiation threshold of 350.
A summary of eligibility criteria is presented in table 2.
We excluded patients at risk of documented serious side
effects of the regimes used. This includes patients with
abnormal kidney function (eg, a creatinine clearance
rate above 60.0 mL/min), taking medication for
multidrug-resistant tuberculosis, testing positive for hepa-
titis B (PrEP only) or being prescribed any other drugs
contraindicated for taking with any of the drug regimens
prescribed in the study. Patients are also excluded at clini-
cian’s discretion according to their assessment of the
patient’s safety. We also exclude FSWs pregnant at enrol-
ment. All pregnant women are referred to antenatal care,
where HIV-positive FSWs are started on ARTas per guide-
lines and HIV-negative FSWs counselled.
Intervention
Recruitment
Participants for both arms of the study are recruited
from the local Wits RHI Sex Worker Project clinics as
well as the surrounding community, and in particular
places of business such as hotels/brothels, bars and
streets. We leverage the existing peer educator-based out-
reach services currently provided by the Sex Worker
Project to reach out and inform them of the study. Each
potential participant completes a DoH HIV counselling
and Testing (HCT) consent form ﬁrst as part of standard
HCT practice, to determine HIV status through the
Table 1 Sample size considerations
PrEP arm ITx arm
Retention at 12 months (%) Precision (%) Number Retention at 12 months (%) Precision (%) Number
65 2.5 1398 75 2.5 1152
65 5.0 350 75 5.0 288
65 7.5 155 75 7.5 128
65 10.0 87 75 10.0 72
Numbers in bold are the numbers taken to develop the sample size.
ITx, immediate treatment; mo, months; N, number; PrEP, pre-exposure prophylaxis.
Table 2 TAPS Project eligibility criteria
PrEP arm ITx arm
18 years or older 18 years or older
Creatinine clearance above
60.0 mL/min
Creatinine clearance above
60.0 mL/min
Negative for hepatitis B CD4 count above national
standard for ART initiation
Not pregnant Not pregnant
Not presenting signs or
symptoms of or taking
medication for MDR-TB
Not presenting signs or
symptoms of or taking
medication for MDR-TB
Not prescribed other drugs
contraindicated for taking
with emtricitabine and
tenofovir disoproxil fumarate
(FTC/TDF)
Not prescribed other drugs
contraindicated for taking
with tenofovir disoproxyl
fumarate/lamivudine/
emtricitabine/efavirenz (TDF
+3TC/FTC+EFV)
ART, antiretroviral therapy; ITx, immediate treatment; MDR-TB,
multidrug resistant tuberculosis; PrEP, pre-exposure prophylaxis.
Gomez GB, et al. BMJ Open 2016;6:e011595. doi:10.1136/bmjopen-2016-011595 3
Open Access
point-of-care rapid testing process. Discordant HIV rapid
test results are then conﬁrmed using ELISA using stand-
ard local algorithms (ie, algorithm: two rapid tests are
performed simultaneously for conﬁrmation. In case of
discordant, indeterminate or positive results, blood is
drawn for an ELISA).34 Once HIV status is established,
participants sign either the PrEP or ITx TAPS study
informed consent form according to HIV status.
Participants in the PrEP arm are counselled and
informed about adherence and effectiveness of PrEP,
the need to use condoms with PrEP in order to ensure a
high level of protection against HIV infection as well as
to prevent STIs and unwanted pregnancies. Participants
in the ITx arm are also counselled about adhering to
their treatment regimens and using condoms.
We aimed to balance the ‘real world’ aspect of the
demonstration project with the consent and information
gathering needs for research purposes. Therefore, at the
screening visit, participants are asked to complete a
demographic and behaviour questionnaire, as well as a
short medical history for screening purposes. Blood
samples are taken for creatinine levels, hepatitis B, syph-
ilis testing, HIV conﬁrmation with ELISA and viral load
testing. All participants also take a point-of-care preg-
nancy test as part of eligibility requirements.
Participants are asked to return in 1-week, within a
maximum window of up to 30 days if needed, after the
screening visit for enrolment if eligible. At the enrol-
ment visit, participants are scheduled for regular study
visits to monitor medication adherence and safety. We
also take a clinical history, offer syndromic STI screening
and any other clinically indicated assessments such as
for cervical cancer as per DoH guidelines. Potential par-
ticipants are asked about fertility intentions; however,
future pregnancy plans are not a part of study exclusion.
Contraception is offered to those requiring a method as
per standard of care, but use of a contraceptive is not a
requirement for study eligibility.
The participants have access to counselling services, as
well as all other services provided by the Sex Worker
Project as standard of care, including but not limited to
reproductive health services, referrals for legal services,
substance use and violence counselling and support and
post-rape care. Support groups are not currently
planned as an ofﬁcial service of this study; however,
FSWs may elect to form support groups and project staff
make an effort to support this with space if requested.
Medication and adherence
HIV-negative participants fulﬁlling all eligibility criteria
are started on co-formulated emtricitabine and tenofovir
disoproxyl fumarate FTC/TDF (Truvada) in the PrEP
arm. The medication for the ITx arm is tenofovir diso-
proxyl fumarate plus lamivudine/emtricitabine plus efa-
virenz combination (TDF+ 3TC/FTC+EFV), or Atripla,
as per current guidelines. The drugs for the TAPS study
have been donated by Gilead.
We measure adherence to PrEP through several
modes of self-report as well as plasma drug level testing.
Treatment adherence is measured through self-report
and monitoring viral load suppression.
As adherence support, all participants have the option
to receive SMS. Two types of SMS may be sent to partici-
pants. The ﬁrst type is visit reminders, three sent per
visit—two as reminders before the visit and one to thank
the participant for attendance or to remind them to
reschedule if they missed a visit. The second type is
aimed at providing information and support on a weekly
basis and within the following themes—adherence/side-
effects/informational, health education, healthy living,
referral services and afﬁrmations. All participants are
offered each type of messaging services and those who
are willing to participate sign an additional consent
form. Participants are able to opt out at any time and
feedback on the utility of the messages is solicited
throughout the study.
Management of pregnancy
Guidance from major organisations, such as the WHO
and Centers for Disease Control and Prevention (CDC),
USA, has made surveillance of PrEP use in pregnancy a
priority.35 36 If a participant becomes pregnant during
the course of the project in the PrEP group, she will be
given the option to either continue or discontinue
taking PrEP. If she decides to discontinue PrEP, she will
be given the option to remain in the project using other
HIV prevention options, but is referred for antenatal ser-
vices or termination of pregnancy services as selected.
The potential for harm due to unknown risks of taking
PrEP while pregnant is noted in the main study’s
informed consent forms.
If a participant in the treatment group becomes preg-
nant during the course of the project, she will also be
given the option to remain in the study and be referred
for antenatal services, where participants will continue
lifelong treatment as per the current guidelines. If the
participant decides to discontinue participation in the
study, she will be referred to the clinic of her choice for
continued treatment.
Follow-up visits and loss to follow-up
Participants are scheduled for clinic visits on a 3-month
basis and receive a prescription reﬁll once a month in
both arms. Monitoring visits include HIV testing (PrEP
arm only), CD4 and viral load tests (ITx arm only), cre-
atinine levels, syndromic screening and treatment for
STIs as required, and adherence counselling. All these
services are standard of care for monitoring patients on
treatment and are the minimum monitoring require-
ment in the newly published PrEP and ITx guidelines.23
At each scheduled visit, participants are asked to com-
plete a short questionnaire to record any side effects,
changes in risk behaviour, fertility intentions, time of last
menstrual period and adherence to ARVs. Participants
may also request an unscheduled visit to report safety
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events at any time. We are not collecting quantitative
information on diversion of medications (eg, selling or
giving ARVs to others), but we are both collecting quali-
tative information on this important issue as part of the
in-depth interviews (IDIs) and providing intensive adher-
ence counselling.
Loss to follow-up is deﬁned as a participant missing
two consecutive visits with no contact. Efforts will be
made to contact participants by phone in the PrEP and
ITx arms to understand the reasons for missed visits.
However, only additional efforts, which may include a
home visit, will be made to encourage participants in
the ITx arm to return. If participants are contacted in
the PrEP group and decide not to return, we will ask if
they are willing to participate in a brief exit interview to
understand the reasons for dropout and to ensure there
are no safety concerns.
Final visit and withdrawal from the project
At the ﬁnal project visit, all participants will be asked to
answer ﬁnal behavioural, violence and participant
costing questionnaires. Those in the PrEP arm will have
creatinine test, STI screening and treatment as neces-
sary; while those in the treatment arm will have CD4
and viral load tests, creatinine test, STI screening and
treatment as necessary, and counselling for continued
adherence to their treatment regimen. They will be
offered a choice to remain at the same clinic for contin-
ued care and treatment, or be transferred to another
clinic of their choice. If a participant in the PrEP arm
sero-converts, we will offer a full resistance testing. The
participant will not be rolled on to the ITx arm but will
be offered a choice to remain at the same clinic for con-
tinued care and treatment, or be transferred to another
clinic of their choice. All participants will also be
informed as to when they can expect a report of the pro-
ject’s results.
As of 1 June 2016, PrEP and the test and treat approach
has been prioritised for sex workers. As a result, we are
now able to transition all of the women in our study to
PrEP and HIV treatment services in our Sex Worker
Programme or to other clinics of their choosing offering
these services, either at the end of the study or should
they choose to leave the study early for any reason.
For ease of reference, we mapped all events and pro-
vided a visit schedule for both PrEP arm and ITx arm in
the online supplementary appendix.
Analysis
The project is being evaluated through a mixed
methods approach. This approach examines the deliver-
ability of the interventions and their integration into a
comprehensive prevention and treatment package, and
includes quantitative analysis of process and question-
naire data (behaviours, uptake, linkage and retention in
care and adherence), qualitative assessment of providers
and user feedback on the interventions, and an eco-
nomic evaluation from a societal perspective.
Quantitative analysis of process and questionnaire data
The primary outcome for both arms is the number of
women retained at 12 months of follow-up (a participant
is considered retained at 12 months if she attended a
scheduled follow-up visit between 10.5 and 13.5 months
after enrolment). In the PrEP arm, we note that a par-
ticipant is considered retained even if not on PrEP but
continuing the combination prevention visits. Secondary
outcomes for both arms are shown in table 3.
We can expect three types of bias in cohort studies:
selection bias, information bias and misclassiﬁcation
bias. It is possible that participants ‘auto-select’ (ie, a
selection bias), meaning that those FSWs feeling most
vulnerable will be most likely to enrol and continue par-
ticipation. Since this is a demonstration project, we
expect participants to decide whether to participate
based on their risk perception and we will aim to docu-
ment these motivations and perceptions as much as pos-
sible through qualitative research. We do not expect an
information bias to be present as we are collecting the
same information for all participants. Finally, misclassiﬁ-
cation could arise from a participant being considered
not retained in care as per her participation in our
study; however, she might be in care at another clinic.
We will aim to ascertain if this is a potential bias while
contacting by phone those participants missing two con-
secutive clinic visits in either the PrEP or the ITx arm to
understand the reasons for missed visits.
Qualitative research
Data from qualitative research conducted during the
PrEP efﬁcacy trials indicate multiple and varying reasons
for lack of adherence on the part of participants, thus
illustrating the imperative to understand how PrEP may
be best implemented in a given context from the point of
view of potential consumers.37 38 In this regard, we are
conducting a multifaceted qualitative research with parti-
cipants from the two project arms as well as providers at
the clinics to gain perspectives on using and implement-
ing PrEP and ITx. Methods include IDIs with partici-
pants, waiting-room observations and provider group
discussions. These methods will serve as a means to
compare and contrast sources of data to develop a narra-
tive as to the feasibility, and more speciﬁcally, the motiva-
tions and barriers of implementing PrEP and ITx. We will
also be able to compare these qualitative data with data
from the structured questionnaires to explore different
aspects of adherence to medication. All data collection
tools have been piloted and adjusted as required.
Participant IDIs
We use an adapted socioecological model as a frame-
work to explore themes related to motivations and bar-
riers to the use of PrEP and ITx based on the multiple
spheres inﬂuencing women’s lives from community,
household, work and clinic settings. A subset of women
from the PrEP and ITx arms are being randomly invited
to participate in the qualitative research component in
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each arm (up to 40 for PrEP and up to 30 for ITx).
Each participant is asked to sign a separate consent
form and is reimbursed for her travel costs since this will
be outside of regular clinic visit requirements. This is
the only form of participant reimbursement offered
since the purpose of the TAPS project is to assess reten-
tion in the programme in a ‘real-world’ clinic setting.
Interviews are conducted individually with each partici-
pant by a research assistant who is conversant in the par-
ticipant’s language.
Interviews will be conducted longitudinally at months
3, 6 and 9 for each participant in order to explore
themes emerging over time.37 Interview questions will
seek data related to reasons for participating in the
Table 3 TAPS Project secondary outcomes
Variable PrEP arm ITx arm Type of data
Knowledge Assessment of HIV knowledge
including PrEP
Assessment of HIV knowledge
including ITx
Qualitative data (IDIs)
and questionnaire data
Uptake and
acceptability
Description of reasons for ineligibility
after first eligibility assessment
Description of reasons for ineligibility
after first eligibility assessment
Questionnaire data,
complemented by
qualitative data
Proportion of women accepting PrEP
at baseline
Proportion of women accepting ITx at
baseline
Programme data,
complemented by
qualitative data
Comparison demographic
characteristics of women accepting
PrEP vs refusing at baseline
Comparison demographic
characteristics of women accepting
ITx vs refusing at baseline
Questionnaire data
Retention Proportion of women retained and
adherent to PrEP at 3, 6, 18,
24 months
Proportion of women retained and
adherent to ART at 3, 6, 18,
24 months
Programme data
Patterns of use Proportion of women using PrEP
continuously for 12 months
NA Programme data
Description of length of use and
repetitive uptake for women not using
PrEP continuously for 12 months
Programme data and
IDIs
Adherence Proportion of women reporting taking
>85% of pills (self-reported) at each
routine visit during 12 months
Proportion of women reporting taking
>85% of pills (self-reported) at each
routine visit during 12 months
Questionnaire data
Proportion of women with drug level
detectable in plasma at 12 months
Proportion of women with
undetectable viral load at 12 months
Clinical (laboratory)
data and IDIs
Side effects Number (by type) of all side effects
reported at routine visits for 12 months
Number (by type) of all side effects
reported at routine visits for
12 months
Clinical data, IDIs and
clinic observations
HIV status Number of seroconversion cases at
12 months and description of all
resistance profiles
Proportion of women with plasma
HIV-1 RNA level≥1000 copies/mL at
6 months or after initial suppression
and description of all resistance
profiles
Clinical (laboratory)
data
Pregnancy Pregnancy rates during follow-up Pregnancy rates during follow-up Clinical data
Sexual behaviour Comparison of proportion of women
reporting consistent condom use
(stable partners, regular/new clients):
baseline vs PrEP use after 12 months
Comparison of proportion of women
reporting consistent condom use
(stable partners, regular/new clients):
baseline vs ART use after 12 months
Questionnaire data
and IDIs
Proportion of women presenting with
STI symptoms at each routine visit
during 12 months
Proportion of women presenting with
STI symptoms at each routine during
12 months
Questionnaire data
Cell phone
technology for
adherence support
Proportion of women opting-out of
SMS reminders at baseline and
throughout the duration of the project
Proportion of women opting-out of
SMS reminders at baseline and
throughout the duration of the project
Programme data and
IDIs
Cost of
intervention
Cost per person-year on PrEP (health
service perspective)
Cost per person-year on ITx (health
service perspective)
Costing data
Cost per person-year on PrEP
(participant perspective)
Cost per person-year on ITx
(participant perspective)
Costing questionnaire
data
ART, antiretroviral therapy; IDIs, in depth interviews; ITx, immediate treatment; NA, not applicable; PrEP, pre-exposure prophylaxis; STI,
sexually transmitted infection.
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study, motivations and barriers to uptake and use of the
interventions, acceptability of the SMS technology, per-
ceived gaps in service delivery and HIV prevention
method preferences over time. Interviews will be audio
taped, and later translated into English, as needed, and
transcribed.
Waiting-room observations
Informal conversations held by participants in settings
such as waiting-rooms have provided invaluable informa-
tion for the triangulation of qualitative data thus enrich-
ing narratives of participant behaviour during studies.37
We are conducting waiting-room observations at the two
project sites for a period of 1-week on a quarterly basis.
Permission to conduct these observations is obtained
from the clinic managers, and researchers conducting
the observations provide study participants in the
waiting-rooms with notiﬁcation of who they are, what
they are doing and for what purpose. The purpose of
these observations is to gather informal data on partici-
pants’ perspectives of the study, the interventions and
issues they may be experiencing that inﬂuence their
interest in the programme and ability to maintain par-
ticipation. Information will be recorded in the research-
er’s ﬁeld notebook and later uploaded into NVIVO for
coding and analysis.
Provider group discussions
A recent guidance illustrates the importance of service
delivery providers as an important target group for pro-
moting and managing the dissemination and uptake of
PrEP.39 As such, we are convening informal group discus-
sions at each site in order to explore provider experi-
ences, including primarily the community health
workers/counsellors, nurses, pharmacists, coordinators
and medical ofﬁcers, in delivering PrEP and ITx. All
potential provider-participants are asked to complete the
informed consent process and have the option to
decline participation. The research is being conducted
by an external contractor and does not include evalu-
ation of providers on performance. As themes for discus-
sion may evolve over time, a more structured discussion
guide is being used initially and subsequent guides will
build on emerging themes.
Analysis
All qualitative research components will be analysed
using thematic analysis as deﬁned by Braun and
Clarke.40 This approach to thematic analysis features a
six-phase process: familiarisation with the data, gener-
ation of initial codes, searching for themes, reviewing
themes, deﬁning and naming themes, and ﬁnally produ-
cing the report. Translated and transcribed transcripts
from the IDIs, waiting-room observations and provider
group discussions will be uploaded into NVIVO software
and coded according to the coding manual created.
Researchers will assemble the coding manual ﬁrst by
developing overarching data categories based on
research objectives, then by systematic and iterative
review of the data to elicit primary and subthemes. We
will aim to have at least two coders per transcript. Any
discrepancies in coding will be discussed between the
coders with input from the senior investigator to gain
consensus. Once all the data have been coded, research-
ers will synthesise the ﬁndings to explore commonalities
and differences across participant perspectives.
Economic evaluation
The introduction of an integrated HIV prevention and
care service is likely to involve several trade-offs between
costs and efﬁciencies. We are measuring empirically the
costs for participants and the healthcare providers in the
two sites of the TAPS study to then model total costs,
impact and cost-effectiveness of this intervention both in
our cohort and at a population level. The evaluation is
carried out from a societal perspective.
Healthcare provider costs
All costs will be estimated using an ingredient costing
approach to deﬁne the cost per person receiving each
service. Data are collected through directly observed
resource use (observations of practice at sites and inter-
views with the healthcare workers before implementa-
tion, at early stages of implementation and 1-year after
the interventions are implemented). We also review
clinic costs (such as utility bills) over the duration of the
study. We include capital costs (equipment, buildings,
non-recurrent training), as well as recurring costs (per-
sonnel, supplies, operations and maintenance of build-
ings) in our estimates. We aim to include costs incurred
above the direct service level, such as monitoring and
evaluation and coordination costs as well as cost
incurred during start up activities such as community
mobilisation and training before the service delivery
starts. The current micro costing approach allows us to
record in detail all processes happening at each visit and
their purpose (for research or service delivery). The
unit cost will then be reported disaggregating
research-related costs.
Participant costs
Data are collected through voluntary questionnaires
administered to all participants in the PrEP and ITx
cohorts at one visit (follow-up at 12 months). In the
questionnaires, we collect general information regarding
the participant’s household, employment and income,
out-of-pocket expenditures including transportation
fees, consultation fees, non-HIV laboratory tests,
non-HIV medication (vitamins, antibiotics and others)
and food, any time lost due to PrEP or ITx appoint-
ments, including travel time, consultation time and loss
of income: the participant’s time and that of her family/
friends will be ascertained. Family/friends time will be
estimated from the proportion of visits where a family
member/friend escorted the participant.
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Modelling
All modelling exercises will be informed from the data
collected during the TAPS study on behaviour, uptake,
linkage, retention and medication adherence as well as
the costing data. A decision analytic economic modelling
approach will be used to look at issues of health system
capacity (staff constraints) and equity (poverty analysis
using patient-related costs within the cohort). The direct
impact on costs and health gains that the introduction of
PrEP and ITx might have had on the study cohorts and
the service provided in the clinics will be explored.
A population-level transmission model ﬁtted to the
South African epidemic will be used, with a special
emphasis on transmission within FSW groups with high
mobility model focusing on the estimated impact that
the introduction of PrEP and ITx might have, should
the intervention be scaled up nationally. Population-level
data will be gathered from the literature. Outputs of the
transmission model will include cost-effectiveness and
budget impact measures. A series of scenario analyses
might be needed to reﬂect the different strategies for
scale up that policymakers might consider. We will
consult all stakeholders (both users and policymakers)
during the process of deﬁning the scenarios for scale up
to ensure that the most realistic scenarios are tested. We
will aim to estimate the reduction in health costs of
implementing both interventions. Therefore, we expect
savings from infections averted while on PrEP and from
less ‘other’ HIV care if treatment is started early.
ETHICS AND DISSEMINATION
Ethical considerations
As an implementation science research study including
human subjects and medication, this study has taken all
ethical issues into consideration in line with ICH-GCP (The
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) - Good Clinical Practice) guidelines.
These include the risks and beneﬁts of taking the
study medications as well as the participation in the study
itself, the informed consent process, maintaining conﬁ-
dentiality and participation reimbursement. This proto-
col has been reviewed and approved by the Wits Human
Research Ethics Committee (HREC—reference number:
140502) and the Medicines Control Council (MCC—
reference number: 20140740), South Africa. The proto-
col was initially approved by both committees on
8 September 2014, and 15 October 2014 respectively. An
amendment was approved subsequently (16 March 2016)
following MCC approval of new indication for FTC/TDF
and changes in DoH treatment-eligibility criteria.
As this project is not a clinical trial but rather an imple-
mentation study, using a product not registered for the
relevant indications in South Africa at the time of ethical
and MCC applications, the requirements for ethical and
MCC approvals were unclear. As with other demonstra-
tion projects globally, the project was held to clinical trial
standards during the course of the review with questions
about procedure, monitoring and participant support
throughout the process. In particular, the project is
seeking to evaluate the willingness of FSW’s to take up
and use PrEP and ITx; therefore, we were strongly com-
mitted to delivering the interventions in a ‘real-world’
context which meant excluding reimbursements for
clinic visits. This had to be negotiated with the ethics and
MCC committees, where a participant fee was suggested,
based on the guarantee of minimal invasive procedures
(eg, nothing outside of what would be carried out rou-
tinely in a public health clinic) and limited waiting time
spent in the clinics. In the end, it was agreed that partici-
pants would not be paid given the project was offering
new interventions for free on top of routine services, but
those participants participating in the IDIs would be
reimbursed for transport costs at R50.
Owing to the vulnerable nature of this population, con-
ﬁdentiality was an important factor to incorporate into all
aspects of the project, but in particular the design of clin-
ical processes. All staff members, whether in contact with
participants or not, were trained on how to maintain con-
ﬁdentiality of participants and all patient ﬁles, question-
naire data and specimens are being labelled and
managed in such a way to safeguard identities.
Dissemination
A stakeholder engagement plan has been implemented
as part of the project, which includes the formation of a
sex-worker focused community advisory board (CAB),
engagement with ofﬁcials in the South African health
sector both at the national and local levels, engagement
with partners and stakeholders at the international level,
and continuous community outreach and education in-
cluding sensitisation trainings for community members
and Wits RHI staff. The engagement nationally and
internationally has included participation on WHO
guidelines committees, South African DoH guidelines
committees for PrEP and ITx and the new National Sex
Worker Plan, as well as plenaries and other presentations
at international and local conferences.
The stakeholder engagement plan also includes the
dissemination of information about the study as it pro-
gresses through the channels mentioned above, as well
as eventual dissemination of results. Once the study is
completed, study staff will ﬁrst disseminate results to
TAPS participants. This may be carried out through
meetings or SMS. Results will be presented to local
health ofﬁcials and stakeholders at meetings, and then
sent out through press releases to other partners.
Finally, investigators will publish the main study results
as well as ﬁndings from the multiple research compo-
nents of the study, namely the economic evaluation,
qualitative research and other clinical and process data.
Results from the study will also be presented at various
conferences. We will aim to follow STROBE guidelines
in the presentation of results; these guidelines were fol-
lowed in developing the protocol.41
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